Video: Polio Vaccines Set to Strengthen Indonesia's Position in Global Supply Chain

CNBC Indonesia held a Health Forum titled “BPOM Achieves WLA Status, What Are the Benefits for Businesses?” to examine the implications of Indonesia’s pharmaceutical and food regulatory authority (BPOM) securing recognition from the global health body and its inclusion on the WHO Listed Authority (WLA) register.

The forum explored how BPOM’s elevation to WLA status strengthens Indonesia’s position in the global vaccine supply chain. The discussion featured a dialogue led by Shafinaz Nachiar with William Adi Teja, Deputy Head of Drug, Narcotics, Psychotropic, Precursor and Addictive Substance Oversight at BPOM, alongside Shadiq Akasya, Chief Executive of Bio Farma, FX Sudirman, Chief Executive of Biotis Pharmaceuticals Indonesia, and Andreas Donny Prakasa, Director of Corporate Relations and Strategic Affairs at PT Etana Biotechnologies Indonesia, during the CNBC Indonesia Health Forum held on Friday, 27 February 2026.

The WLA status recognition positions Indonesia’s pharmaceutical regulatory framework as compliant with international standards, potentially opening pathways for Indonesian vaccine manufacturers to participate more directly in global supply chains and international procurement mechanisms, including those of organisations like GAVI and UNICEF.